We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
-7.11%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$237M
AUM Growth
-$388M
Cap. Flow
-$68.1M
Cap. Flow %
-28.7%
Top 10 Hldgs %
53.02%
Holding
76
New
17
Increased
16
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$11.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.31M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.26M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.84M
5
LNTH icon
Lantheus
LNTH
+$1.58M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$13.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.1M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.98M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.96M
5
AZN icon
AstraZeneca
AZN
+$4.92M

Sector Composition

Rank Sector Weight
1 Healthcare 63.86%
2 Miscellaneous 34.69%
3 Financials 1.44%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
51
CALL
Aurinia Pharmaceuticals
AUPH
$2.14B
– –
-175,000
Closed -$2.17M
BEAM icon
52
CALL
Beam Therapeutics
BEAM
$3.06B
– –
-30,000
Closed -$1.72M
BPMC
53
DELISTED
Blueprint Medicines
BPMC
– –
-1,988
Closed -$127K
CNTA
54
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-65,282
Closed -$586K
BGMS
55
Bio Green Med Solution Inc
BGMS
$5.98M
– –
-111
Closed -$1.22M
HYPR icon
56
Hyperfine
HYPR
$86.2M
– –
-76,162
Closed -$270K
OBIO icon
57
Orchestra BioMed
OBIO
$305M
– –
-300,000
Closed -$2.97M
PMVP icon
58
CALL
PMV Pharmaceuticals
PMVP
$69M
– –
-317,400
Closed -$6.61M
PTGX icon
59
Protagonist Therapeutics
PTGX
$9.43B
– –
-300,000
Closed -$7.1M
PTGX icon
60
PUT
Protagonist Therapeutics
PTGX
$9.43B
– –
-215,900
Closed -$5.11M
RLAY icon
61
CALL
Relay Therapeutics
RLAY
$4.17B
– –
-75,000
Closed -$2.25M
SPY icon
62
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
– –
-750,000
Closed -$339M
SWTX
63
DELISTED
SpringWorks Therapeutics
SWTX
– –
-247,000
Closed -$13.9M
SWTX
64
PUT
DELISTED
SpringWorks Therapeutics
SWTX
– –
-160,000
Closed -$9.03M
TVTX icon
65
Travere Therapeutics
TVTX
$6.15B
– –
-100,000
Closed -$2.58M
XENE icon
66
Xenon Pharmaceuticals
XENE
$5.79B
– –
-80,000
Closed -$2.45M
CERE
67
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-70,000
Closed -$2.45M
NSTG
68
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-171,592
Closed -$5.96M
MSAC
69
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
– –
-300,000
Closed -$2.93M
GBT
70
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-70,000
Closed -$2.42M
ATHX
71
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-56,656
Closed -$858K
CALA
72
DELISTED
Calithera Biosciences, Inc
CALA
– –
-50,000
Closed -$404K
1 2
3

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Affinity Asset Advisors held 76 positions worth $237M, down 62% from $625M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Affinity Asset Advisors withdrew a net $68.1M in Q2 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $13.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 34% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arcellx worth $1.36M.

  • Affinity Asset Advisors's largest Q2 2022 buy was Arcellx: 75,000 shares worth $1.36M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2022, an estimated $11.8M increase.
  • Affinity Asset Advisors's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $6.98M.
  • Affinity Asset Advisors fully exited SpringWorks Therapeutics in Q2 2022, selling an estimated $13.9M.
  • Affinity Asset Advisors's ten largest holdings make up 53% of its $237M portfolio in Q2 2022.
  • Affinity Asset Advisors opened 17 new positions and closed 22 in Q2 2022.
  • Affinity Asset Advisors's portfolio value fell 62% quarter-over-quarter to $237M.

Based on Affinity Asset Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.